Related and Cogent Publications From the Ovarian Cancer Screening Program
(Click on an hyper-linked article to go to it)

Higgins, R.V., van Nagell, J.R., Donaldson, E.S., Gallion, H.H., Pavlik, E.J., Endicott, B., et. al., Transvaginal sonography as a screening method for ovarian cancer. Gynecol. Oncol., 34, 402-406 (1989).

Higgins, R.V., van Nagell, J.R., Woods, C.H., Thompson, E.A. and Kryscio, R.K., Interobserver variation in ovarian measurements using transvaginal sonography. Gynecol. Oncol., 39, 69-71 (1990).

 van Nagell, J.R., Higgins, R.V., Donaldson, E.S., Gallion, D.E., Pavlik, E.J., et. al., Transvaginal sonography as a screening method for ovarian cancer: a report of the first 1000 cases screened. Cancer, 65, 573-577 (1990).

van Nagell, J.R., DePriest, P.D., Puls, L.E., Donaldson, E.S., Gallion, H.H., Pavlik, E.J., et. al., Ovarian screening in asymptomatic postmenopausal women by transvaginal sonography. Cancer, 68, 458-462 (1991).

DePriest, P.D., van Nagell, J.R. Jr;, Gallion, H.H., Shenson, D., Hunter, J.E., Andrews, S.J., Powell, D.E. and Pavlik, E.J., Ovarian Cancer Screening in Asymptomatic Postmenopausal Women. Gynecol. Oncol., 51,205-209 (1993).

DePriest, P.D., Shenson, D., Fried, A., Hunter, J.E., Andrews, S.J., Gallion, H.H., Pavlik, E.J., Kryscio, R.J., van Nagell, J.R., Jr. A morphology index based on sonographic findings in ovarian cancer.  Gynecol. Oncol. 51:7-11, 1993.

van Nagell and J.R., DePriest, P.D., Early diagnosis of epithelial ovarian cancer. In: M. Markham and W.J. Hoskins (eds) Cancer of the Ovary, pp. 127-131, Raven Press, New York:, (1993).

NIH Consensus Development Panel on Ovarian Cancer. NIH Consensus Conference: Ovarian cancer: screening, treatment, and follow-up.  J. Amer. Med. Assoc., 273, 491-497 (1995).

Pavlik, E.J., van Nagell, J.R., Jr., DePriest, P.D., Wheeler, L., Tatman, J.M., Boone, M., Sollars, S., Rayens, M.K. and Kryscio, R.J., Participation in Transvaginal Ovarian Cancer Screening: Compliance, Correlation Factors, and Costs. Gynecol. Oncol., 57, 395-400 (1995).

van Nagell, J.R., Gallion, H.H., Pavlik, E.J. and DePriest, P.D., Ovarian Cancer Screening. Cancer, 76, 2086-2091(1995).

DePriest, P.D.and van Nagell, J.R., Jr., Ovarian Cancer Screening. Curr. Prob. in Obstet. Gynecol. & Fert., 19,103-109 (1996).

Bailey, C.L., Ueland, F.R., Land, G.L., DePriest, P.D., Gallion, H.H., Kryscio, R.J. and van Nagell, J.R., Jr., Malignant Potential of Small Cystic Ovarian Tumors in Postmenopausal Women. Gynecol. Oncol., 69,3-7 (1998).

Reedy, M., Ueland, F., Pavlik, E.J., DePriest, P.D., Kryscio, R.J. and van Nagell, J.R. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecologic Oncol. 77:350-356, 2000

Pavlik, E.J., DePriest, P.D., Gallion, H.H., Ueland, F.R., Reedy, M.B., Kryscio, R.J & van Nagell, J.R. Ovarian Volume Related to Age. Gynecologic Oncol. 77:410-412, 2000.

Pavlik, E.J., Johnson II, T.L., DePriest, P.D., Andrykowski, M.A., Kryscio, R.J. and van Nagell Jr, J.R. Continuing participation supports ultrasound screening for ovarian cancer. Ultrasound in Obstetrics & Gynecology 15: 354-364 (2000)

Pavlik, E.J., Liu, Chengan., DePriest, P.D, Gallion, H.H., Ueland, F.R., Kryscio, R.J. and van Nagell Jr, J.R. Normal ovarian volume: A smoothing approach applied to data obtained by transvaginal sonography. Gynecologic Oncol. 80: 333-334 (2001).

Studts, J.L., Pavlik, E.J., Andrykowski, M.A. (2001). A measurement tool for assessing knowledge of ovarian cancer risk factors. [abstract] Annals of Behavioral Medicine, 23 (Suppl.), S078.

Studts, J.L., Pavlik, E.J., Andrykowski, M.A. (2001). Perceived cancer risk in women undergoing ovarian cancer screening: A comparison of assessment methods. [abstract] Annals of Behavioral Medicine, 23 (Suppl.), S073.

Spencer, T., Pavlik, E., & Andrykowski, M.A. (2001). Risk perception in an ovarian cancer screening program: Relation to optimism and screening intentions. [abstract] Annals of Behavioral Medicine, 23 (Suppl.), S063.

Boerner, L., Pavlik, E., & Andrykowski, M.A. (2001). Risk knowledge in an ovarian cancer screening program. [abstract] Annals of Behavioral Medicine, 23 (Suppl.), S076.

F.R. Ueland, M.D.,P.D. DePriest, M.D.,E.J. Pavlik, Ph.D.,R.J. Kryscio, Ph.D.,J. R. van Nagell, Jr., M.D. Preoperative Differentiation of Malignant from Benign Ovarian Tumors:  The Efficacy of Morphology Indexing and Doppler Flow Sonography  Gynecologic Oncology 91: 46-50 (2003).

J.L. Wilder, E.J. Pavlik, J.M. Straughn, t. Kirby, R.V. Higgins, P.D. DePriest, F.R. Ueland, R.J. Kryscio, R.J. Whitley, J.R. van Nagell, Jr.  Clinical Implications of a rising serum Ca-125 Within the normal range in patients with epithelial ovarian cancer.  Gynecologic Oncology 89:233-235 (2003).

Modesitt, S.C., Pavlik, E.J., Ueland, F.R., DePriest, P.D., Kryscio, R.J., van Nagell, J.R., Jr.  Risk of malignancy in unilocular ovarian cystic tumors less than 10 cm in diameter.  A long-term follow-up study.  Obstetrics and Gynecology 102: 594-599 (2003).

Chobanian NH, Greenberg VL, Gass JM, DeSimone CP, Van Nagell JR, Zimmer SG.  Histone deacetylase inhibitors enhance paclitaxel-induced cell death in ovarian cancer cell lines independent of p53 status.  Anticancer Res. 2004 Mar-Apr;24(2B):539-45.  

van Nagell JR, DePriest PD.  Management of adnexal masses in postmenopausal women.  Am J Obstet Gynecol. 2005 Jul;193(1):30-5.

Ueland FR, DePriest PD, DeSimone CP, Pavlik EJ, Lele SM, Kryscio RJ, van Nagell JR Jr. The accuracy of examination under anesthesia and transvaginal sonography in evaluating ovarian size.  Gynecol Oncol. 2005 Nov;99(2):400-3. Epub 2005 Aug 9.

Cooper AL, Greenberg VL, Lancaster PS, van Nagell JR Jr, Zimmer SG, Modesitt SC.  In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer.  Gynecol Oncol. 2007 Mar;104(3):596-601. Epub 2006 Oct 16.

Related Articles, Linksvan Nagell JR Jr, DePriest PD, Ueland FR, DeSimone CP, Cooper AL, McDonald JM, Pavlik EJ, Kryscio RJ.  Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened.  Cancer. 2007 May 1;109(9):1887-96.

Salsman JM, Pavlik E, Boerner LM, Andrykowski MA.  Clinical, demographic, and psychological characteristics of new, asymptomatic participants in a transvaginal ultrasound screening program for ovarian cancer.  Prev Med. 2004 Aug;39(2):315-22

Andrykowski MA, Boerner LM, Salsman JM, Pavlik E.  Psychological response to test results in an ovarian cancer screening program: a prospective, longitudinal study.  Health Psychol. 2004 Nov;23(6):622-30.

Gaugler JE, Pavlik E, Salsman JM, Andrykowski MA.  Psychological and behavioral impact of receipt of a "normal" ovarian cancer screening test.  Prev Med. 2006 Jun;42(6):463-70. Epub 2006 Mar 24.

Andrykowski MA, Zhang M, Pavlik EJ, Kryscio RJ.  Factors associated with return for routine annual screening in an ovarian cancer screening program. Gynecol Oncol. 2007 Mar;104(3):695-701. Epub 2006 Dec 4.

Lykins EL, Pavlik EL, Andrykowski MA.  Validity of self-reports of return for routine repeat screening in an ovarian cancer screening program.  Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):490-3